News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
News Conference News ACC 2024 SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve L.A. McKeown April 07, 2024
News Conference News ACC 2024 Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock Caitlin E. Cox April 07, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023
News Conference News ACC 2023 ‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk Caitlin E. Cox March 10, 2023
News Conference News ACC 2023 HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension Todd Neale March 08, 2023
News Conference News ACC 2023 Free Meds Don’t Reduce CV Events, but Tailored Messaging Does: ACCESS Caitlin E. Cox March 05, 2023
News Conference News ACC 2023 RAPID-HF: Rate-Adaptive Pacing Doesn’t Help in HFpEF Todd Neale March 05, 2023
News Conference News ACC 2023 Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients Todd Neale March 05, 2023
News Conference News ACC 2023 TRILUMINATE Pivotal: TEER With the TriClip Benefits Patients With Severe TR Todd Neale March 04, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2022 BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short Todd Neale April 11, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes Michael O'Riordan April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs Todd Neale May 18, 2021